Mesenteric Parametrial Fat Pad Surgery for in vivo Implantation of Hepatocytes in Nude Mice.
Hepatocyte
Hydrogel
Implantation
In vivo imaging
Nude mice
Parametrial fat pad
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
12
09
2023
revised:
13
12
2023
accepted:
20
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
epublish
Résumé
Cell-based liver therapies utilizing functionally stabilized engineered hepatic tissue hold promise in improving host liver functions and are emerging as a potential alternative to whole-organ transplantation. Owing to the ability to accommodate a large ex vivo engineered hepatocyte mass and dense vascularization, the mesenteric parametrial fat pad in female nude mice forms an ideal anatomic microenvironment for ectopic hepatocyte transplantation. However, the lack of any reported protocol detailing the presurgical preparation and construction of the engineered hepatic hydrogel, fat pad surgery, and postsurgical care and bioluminescence imaging to confirm in vivo hepatocyte implantation makes it challenging to reliably perform and test engraftment and integration with the host. In this report, we provide a step-by-step protocol for in vivo hepatocyte implantation, including preparation of hepatic tissue for implantation, the surgery process, and bioluminescence imaging to assess survival of functional hepatocytes. This will be a valuable protocol for researchers in the fields of tissue engineering, transplantation, and regenerative medicine. Key features • Primary human hepatocytes transduced ex vivo with a lentiviral vector carrying firefly luciferase are surgically implanted onto the fat pad. • Bioluminescence helps monitor survival of transplanted hepatic tissue over time. • Applicable for assessment of graft survival, graft-host integration, and liver regeneration.
Identifiants
pubmed: 38268979
doi: 10.21769/BioProtoc.4925
pii: e4925
pmc: PMC10804310
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e4925Informations de copyright
©Copyright : © 2024 The Authors; This is an open access article under the CC BY-NC license.
Déclaration de conflit d'intérêts
Competing interestsRobert E. Schwartz is on the scientific advisory board of Miromatrix Inc. and Lime Therapeutics and is a speaker and consultant for Alnylam Inc. The remaining authors have no conflict of interest to declare.